Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

British Biosimilars Association (BBA) appoints new vice-chair

(London – April 03, 2019) The British Biosimilars Association (BBA), the representative group of biosimilar manufacturers in the UK, has announced that Matthew Eddleston will become its new vice-chair with immediate effect.

Matthew is the Biosimilars Business Unit Lead at Fresenius Kabi, (UK & Ireland) having previously been at Pfizer where he was the Biosimilars Regional Commercial Director for Northern Europe. Matthew’s first senior leadership role in Biosimilars began in 2014, as Hospira’s Head of Market Access, UK, Benelux and Ireland.

Matthew brings healthcare leadership over a 20 year career to date, working across key commercial roles in both the generic and pharma sectors. Skilled in the development and execution of strategic commercial and operational programmes, Matthew has recently established Fresenius Kabi’s Biosimilar Business Unit and previously implemented the market access strategy for the European launch of the World’s first Biosimilar monoclonal antibody.
Matthew, who graduated with a dual bachelor’s degree in International Business from Hull Business School and Auckland University, in New Zealand, said: “I am really pleased to be taking the vice-chair role at the British Biosimilars Association. 

“As a collective, the group has made great strides in the last few years in ensuring uptake and access to these important medicines is effective as possible. The UK manufacturing industry has been a collaborative contributor alongside the NHS, NICE and other key partners and I look forward to that continuing into the future.” 

Matthew replaces Andrew Roberts in the vice-chair role and Kavya Gopal remains as the chair of the association.
Warwick Smith, Director General of the BBA, said: “Matthew has already been a valued and active member of the association and we look forward to him further contributing in the role of vice-chair. I would also like to thank Andrew Roberts for his enthusiasm and expertise since the association was first formed.”

About the BBA   
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars.  The members of the BBA ensure access for UK patients to high quality and effective biosimilar medicines that meet robust European safety standards. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and optimised use of biosimilar medicines across the UK.

For further information please contact Jeremy Durrant on 02078667883 / 07792918648